Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response

Overview

Journal Curr Cancer Drug Targets

Publisher Bentham Science Publishers

Specialty Oncology

Date 2007 Feb 20

PMID 17305480

Citations 88

Authors

Shreya Kanodia

Laura M Fahey

W Martin Kast

Affiliations

Soon will be listed here.

Abstract

The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved to escape immune attack by a combination of stealth and interference. This review focuses on the mechanisms by which HPV can evade recognition by the host immune system.

Citing Articles

Human papillomavirus infection affects the immune microenvironment and antigen presentation in penile cancer.

Guimaraes S, Vale A, Rocha M, Butarelli A, da Silva J, de Deus A Front Oncol. 2024; 14:1463445.

PMID: 39493451 PMC: 11527599. DOI: 10.3389/fonc.2024.1463445.

HPV-YAP1 oncogenic alliance drives malignant transformation of fallopian tube epithelial cells.

He C, Lv X, Liu J, Ruan J, Chen P, Huang C EMBO Rep. 2024; 25(10):4542-4569.

PMID: 39271776 PMC: 11467260. DOI: 10.1038/s44319-024-00233-3.

The HPV viral regulatory mechanism of TLRs and the related treatments for HPV-associated cancers.

Qi S, Yang M, Li C, Yu K, Deng S Front Immunol. 2024; 15:1407649.

PMID: 38812510 PMC: 11133576. DOI: 10.3389/fimmu.2024.1407649.

QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial.

Fang C, Zhou Y, Feng Y, He L, Yu J, Li Y J Gynecol Oncol. 2024; 35(6):e77.

PMID: 38606822 PMC: 11543260. DOI: 10.3802/jgo.2024.35.e77.

Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1.

Ha J, Kaser E, Guan T, Mayberry T, Smith L, Dmello K Med Oncol. 2024; 41(3):65.

PMID: 38281234 DOI: 10.1007/s12032-023-02276-3.